Secondhand Cannabis Smoke Exposure for Healthy Subjects

(CAN03 Trial)

Overseen By Abel Huang, BS

Age: 18 - 65

Sex: Any

Trial Phase: Academic

Sponsor: University of California, San Francisco

Must not be taking: Cannabis, CBD, THC, others

Disqualifiers: Asthma, Heart disease, Hypertension, Diabetes, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 2

200 Participants Needed

Trial Summary

Do I have to stop taking my current medications for the trial?

The trial does not specify if you need to stop taking your current medications, but it excludes those using cannabis products or more than two psychiatric medications.

Is secondhand cannabis smoke exposure safe for humans?

Research shows that secondhand cannabis smoke can lead to increased exposure to fine particles (PM2.5), which may affect respiratory health. Studies have found that children in homes with indoor cannabis smoking may have higher odds of adverse health outcomes, although more research is needed to confirm these findings. ^{1 2 3 4 5}

How does secondhand cannabis smoke exposure differ from other treatments for this condition?

Secondhand cannabis smoke exposure is unique because it involves passive inhalation of cannabis smoke by non-smokers, which can lead to detectable levels of THC in their system without them actively using cannabis. This differs from other treatments as it does not involve direct consumption or administration of cannabis products. ^{1 2 6 7 8}

What is the purpose of this trial?

This is an unblinded pilot study of an environmental exposure to secondhand cannabis smoke in one group of healthy nonsmokers.

Research Team

Suzaynn F Schick

Principal Investigator

University of California, San Francisco

Eligibility Criteria

This trial is for healthy adult nonsmokers aged 21-50 with normal blood pressure and BMI, who don't use cannabis or tobacco products, aren't exposed to smoke in their jobs, and have no major health issues like heart disease or diabetes. Pregnant women and those with a history of drug abuse or certain psychiatric conditions cannot participate.

Inclusion Criteria

I am a nonsmoker, aged 21-50, with a BMI between 18.1 and 34.9.

I am a nonsmoker, aged 21-50, with a blood pressure below 150.

I am a healthy adult aged 21-50 and I do not smoke.

Exclusion Criteria

Regular exposure to secondhand tobacco or cannabis smoke

Current illicit drug use (by history or urine test)

Occupational exposure to smoke, dusts OR fumes

Timeline

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Exposure

Participants are exposed to secondhand cannabis smoke in public places for 0.5-4 hours

1 day

1 visit (in-person)

Post-exposure Monitoring

Participants' urinary cannabinoid metabolites are measured the morning after exposure

Up to 22 hours

1 visit (in-person)

Follow-up

Participants are monitored for any delayed effects or additional data collection

1-2 weeks

Treatment Details

Interventions

• Secondhand cannabis emissions/smoke exposure

Trial Overview The study investigates the effects of secondhand cannabis smoke on healthy individuals. Participants will be exposed to this environment without any blinding as part of a pilot study to measure pollutants and exposures from the smoke.

Participant Groups

Group I: Exposure to secondhand cannabis smoke in public places Experimental Treatment 1 Intervention

The research staff and participants will travel together to a public location by either ride share vehicles, taxis or public transit. The study will arrange and pay for the transit. Staff and participants will be exposed to ambient air in public places where cannabis products are being consumed by smoking, vaporizing or dabbing. Participants will remain in the company of the laboratory staff throughout the exposure. The exposures will last 0.5-4 hours, depending on the nature and duration of the event. Staff and participants will travel together back to the laboratory for the post-exposure study measures.

Who Is Running the Clinical Trial?

University of California, San Francisco

Lead Sponsor

Trials

2,636

Recruited

19,080,000+

References

1. Netherlands pubmed.ncbi.nlm.nih.gov

PM2.5 exposure to marijuana smoke on golf courses and other public outdoor locations: A pilot observational study. [2023]

2. England pubmed.ncbi.nlm.nih.gov

Surface Detection of THC Attributable to Vaporizer Use in the Indoor Environment. [2022]

3. Netherlands pubmed.ncbi.nlm.nih.gov

PM2.5 exposure close to marijuana smoking and vaping: A case study in residential indoor and outdoor settings. [2021]

4. England pubmed.ncbi.nlm.nih.gov

Occupational Exposure to Particulate Matter and Volatile Organic Compounds in Two Indoor Cannabis Production Facilities. [2021]

5. United States pubmed.ncbi.nlm.nih.gov

Indoor cannabis smoke and children's health. [2020]

6. United States pubmed.ncbi.nlm.nih.gov

Secondary indoor air pollution and passive smoking associated with cannabis smoking using electric cigarette device-demonstrative in silico study. [2021]

7. Ireland pubmed.ncbi.nlm.nih.gov

Non-smoker exposure to secondhand cannabis smoke II: Effect of room ventilation on the physiological, subjective, and behavioral/cognitive effects. [2022]

8. England pubmed.ncbi.nlm.nih.gov

Nonsmoker Exposure to Secondhand Cannabis Smoke. III. Oral Fluid and Blood Drug Concentrations and Corresponding Subjective Effects. [2022]